AMSTERDAM, Dec. 10, 2015 /CNW/ - myTomorrows (Amsterdam, the Netherlands), announced today that it has started a collaboration with Spectrum Pharmaceuticals, Inc. (Henderson, USA; NasdaqGS: SPPI) to provide access to its liposome-encapsulated vincristine for treatment of Philadelphia chromosome negative acute lymphoblastic leukemia.
In August 2012, the US FDA approved the product for treatment of this rare type of leukemia. Through myTomorrows' Internet-based platform, the product is now also made available to patients and doctors in all other countries of the world, except China, Taiwan and Hong Kong, through an Early Access Program.
"We are pleased to make liposome-encapsulated vincristine also available to leukemia patients outside of the United States, in countries where the treatment did not yet receive market approval," said Dr. Ronald Brus MD, founder and CEO of myTomorrows. "By taking care of the complex and time consuming process of receiving approval from regulatory authorities and healthcare insurers for individual patients, we aim to unburden these patients and their physicians by fulfilling their request as quickly as possible."
Joseph Turgeon, President and COO of Spectrum Pharmaceuticals said "We look forward to expand our collaboration with myTomorrows to also bring this product to doctors and patients through myTomorrows' global platform. It provides an additional option for acute lymphoblastic leukemia patients whose disease is unresponsive to available therapies and underscores Spectrum's efforts to combat this terrible disease."
myTomorrows provides access services to patients and physicians in need of diagnostic tests and drugs in development. The myTomorrows internet platform also offers uniform public information about early access programs, clinical trials and diagnostic tests to enhance data-driven decision making and enables rational pharmacotherapy.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Oncology and Hematology. Spectrum and its affiliates market five oncology drugs. Additionally, Spectrum's pipeline includes three drugs in advanced stages of clinical development. Spectrum's strong track record in-licensing and acquiring differentiated drugs, expertise and proven track record in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at http://www.sppirx.com.
For further information: Contact Erdem Yavuz, +31-88-525-3888, Erdem.Yavuz@mytomorrows.com